A novel dual targeted antibacterial agent for Helicobacter pylori

Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastrointestinal ulcers, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. 1 Malfertheiner P Megraud F Rokkas T et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; (gutjnl-2022-327745.) Crossref Scopus (286) Google Scholar , 2 Yan L Chen Y Chen F et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022; 163: 154-162.e3 Summary Full Text Full Text PDF PubMed Scopus (62) Google Scholar Current guidelines recommend eradication of H pylori, regardless of clinical symptoms. 3 Sugano K Tack J Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64: 1353-1367 Crossref PubMed Scopus (1161) Google Scholar Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trialsRifasutenizol monotherapy and combination therapy was generally safe and well tolerated in healthy participants and patients with H pylori infection. A triple regimen of 400 mg rifasutenizol capsules, 20 mg rabeprazole sodium enteric-coated tablets, and 1 g amoxicillin capsules twice a day for 14 days showed promising efficacy as a new treatment regimen for H pylori infection. Full-Text PDF